online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 16 of 18
Up
ECPB 2013, 62(2): 101–107
Assisting a doctor

Probiotics and metabolic correction of interferon mediated immunity in patients with bronchial asthma

IVASIVKA R.
Abstract

Chronic inflammation of the airways in asthma (BA) causes profound changes interferon system. Normal functioning of the interferon system is as important as immunoregulatory factor and factor resistance of the organism to trigger aggravation – viral and bacterial infections. Characteristic for BA type disorders interferon status is deep depression interferon ability immunocytes. The result of the depletion of interferon is to reduce the resistance to the action of various infectious agents (viruses, bacteria, fungi, etc.), which leads to high risk of repeated infections. When BA is found in serum interferon mainly represented -type, which is the result of nonspecific reactions to infectious and allergenic agents, acting simultaneously as interferon inducers, and can be seen as a defensive reaction. Infectious processes are the cause and effect of interferon deficiency syndromes with full or partial deposition of individual units of interferon.

Under these conditions, it is important to research clinical efficacy of medications with a wide range of biological actions for correction of interferon level in BA. We studied the effect of probiotic “subalin” (live microbial mass culture Bacillus subtilis UKM B-5020, containing plasmid with the gene -2 interferon of a man) and medication of metabolic action “dibikor” (amino acid taurine, which protects interferon from oxidation and thus increases its biological activity) on the key factors of intercellular cooperation in immunopathogenesis of BA: circulating IFN-, IL-4 and IL-10. 77 patients were exami ned, including 36 women and 41 men, mean age 32±4 years, which verified BA. Study design: patients were divided into six representative groups, comparable for gender, age and severity of disease: the IA group (n=14) – patients with intermittent asthma course, IIA (n=12) – åasy persistent of BA, IIIA (n=13) with a verified diagnosis of moderate persistent of BA. For patients in all A groups medical complex included “subalin” to 2 bottles (2•109 living microbial cells) for 40 minutes before meals 3 times a day and “dibikor” 500 mg 2 times a day 20 minutes before meals for 14 days. Group B included patients which were prescribed with only “subalin” rate the same length – IB (n=13), IIB (n=12), IIIB (n=13). Patients with mild to moderate persistent BA were on basic therapy that included inhaled corticosteroids and -agonists, long-acting. The control group consisted of 20 healthy individuals – donors. IFN-, IL-4 and IL-10 were determined in the serum of patients and control individuals using ELISA (STAT-Fax 303 Plus); using test systems “Protein contour” (Russia), «Diaclone» (France). Statistical analysis of the results was carried out with the application package «Statistica» – version 5 for Windows.

In all patients before treatment low compared with the control level of circulating IFN- was revealed, correlating with the severity of BA. Under the influence of 14-day course “subalin” concentration in serum IFN- increased, but in none of the groups it reached the control, significant changes in IL-4 and IL-10 were found. After “subalin” + “dibikor” course in groups IA and IIA IFN- reached the control values, and to treat high concentrations of IL-4 and IL-10 significantly decreased. Reliable change of cytokine balance at boxer dynamics IFN-, IL-4, IL-10 in the serum of patients with intermittent and mild persistent BA, which influenced the course of combined probiotic-metabolic therapy prove feasibility of this therapeutic tactics for correcting interferon level and achieving cytokine-mediated immunoregulation at BA.

Keywords: asthma, interferon, cytokines, probiotics, metabolic drugs

Full text: PDF (Ukr) 189K


Програмування - Roman.im